ERBB2 and neoplasm: Adding trastuzumab to chemotherapy for early-stage HER2-positive breast cancer results in a 30% reduction in breast cancer recurrence and mortality observed across various patient and tumor characteristics, making trastuzumab a valuable treatment strategy [6].